Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab
Harry K. Genant(University of California, San Francisco), Michael R. McClung(Bone Health and Osteoporosis Foundation), José Zanchetta(Universidad del Salvador), S. Stonkus(Klaipėda University), Edward Franek(Mossakowski Medical Research Institute, Polish Academy of Sciences), Hoi-Shen Radcliffe(Amgen (United States)), Michael A. Bolognese, Chui Kin Yuen(University of British Columbia), Klaus Engelke(Friedrich-Alexander-Universität Erlangen-Nürnberg), Arne Høiseth, Thomas Fuerst(Synlab Czech (Czechia)), Cesar Libanati(Amgen (United States))
Cited by 65
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 FOR TREATMENT OF OPEN TIBIAL FRACTURES
|Journal of Bone and Joint Surgery|2002|1.3k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k